Modeling Cardiac Disease Mechanisms Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Progress, Promises and Challenges
Open accessThe DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Abstract
Cardiovascular diseases (CVDs) are a class of disorders affecting the heart or blood vessels. Despite progress in clinical research and therapy, CVDs still represent the leading cause of mortality and morbidity worldwide. The hallmarks of cardiac diseases include heart dysfunction and cardiomyocyte death, inflammation, fibrosis, scar tissue, hyperplasia, hypertrophy, and abnormal ventricular remodeling. The loss of cardiomyocytes is an irreversible process that leads to fibrosis and scar formation, which, in turn, induce heart failure with progressive and dramatic consequences. Both genetic and environmental factors pathologically contribute to the development of CVDs, but the precise causes that trigger cardiac diseases and their progression are still largely unknown. The lack of reliable human model systems for such diseases has hampered the unraveling of the underlying molecular mechanisms and cellular processes involved in heart diseases at their initial stage and during their progression. Over the past decade, significant scientific advances in the field of stem cell biology have literally revolutionized the study of human disease in vitro. Remarkably, the possibility to generate disease-relevant cell types from induced pluripotent stem cells (iPSCs) has developed into an unprecedented and powerful opportunity to achieve the long-standing ambition to investigate human diseases at a cellular level, uncovering their molecular mechanisms, and finally to translate bench discoveries into potential new therapeutic strategies. This review provides an update on previous and current research in the field of iPSC-driven cardiovascular disease modeling, with the aim of underlining the potential of stem-cell biology-based approaches in the elucidation of the pathophysiology of these life-threatening diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“heterogeneity of the iPSC-derived cardiomyocytes, which are mostly composed of atrial, ventricular, and nodal-like cardiomyocytes; cell survival once injected into the damaged area, and obtaining the required cell number [80], all of which may lead to cardiac arrhythmias.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“heterogeneity of the iPSC-derived cardiomyocytes, which are mostly composed of atrial, ventricular, and nodal-like cardiomyocytes; cell survival once injected into the damaged area, and obtaining the required cell number [80], all of which may lead to cardiac arrhythmias.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–212 of 212
Klauke, B., Gärtner, A., Schulz, U., Kassner, A., zu Knyphausen, E., Laser, T., Kececioglu, D., Paluszkiewicz, L., Blanz, U., Sandica, E., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189489 · Cited by 41
Kuroda, Y., Yuasa, S., Watanabe, Y., Ito, S., Egashira, T., Seki, T., Hattori, T., Ohno, S., Kodaira, M., Suzuki, T., et al. (2017) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2017.01.002 · Cited by 40
Characterization of novel KCNH2 mutations in type 2 long QT syndrome manifesting as seizures
Keller, D. I., Grenier, J., Christé, G., Dubouloz, F., Osswald, S., Brink, M., Ficker, E. K., & Chahine, M. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70117-5 · Cited by 39
Notch signaling plays a key role in cardiac cell differentiation
Chau, M. D. L., Tuft, R. A., Fogarty, K. E., & Bao, Z. (2006) · Mechanisms of Development · doi:10.1016/j.mod.2006.06.003 · Cited by 34 · cited 1×
“Serum was later replaced by cytokines and growth factors known to be involved in heart development such as Wnt proteins [38], bone morphogenetic proteins (BMPs) and activin A [31,39], and Notch signals [40], together with their corresponding inhibitors [41,42].”
BackgroundStem Cells: The Game Changers of Human Cardiac Disease Modelling and Regenerative Medicine
Parrotta, E. I., Scalise, S., Scaramuzzino, L., & Cuda, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225760 · Cited by 33 · cited 5×
“Before the advent of iPSC technology, the severity of CVDs together with the lack of efficient treatments rather than transplantation pushed researchers to develop model systems of cardiac diseases comprising animal models for in vivo studies, in vitro cellular models based on the use of stem cells, primary cells, and…”
BackgroundInfluentialSelf-citationA multicentre study of patients with Timothy syndrome
Walsh, M., Turner, C., Timothy, K. W., Seller, N., Hares, D., James, A. F., Hancox, J. C., Uzun, O., Boyce, D. E., Stuart, G., et al. (2017) · EP Europace · doi:10.1093/europace/euw433 · Cited by 32
Fatica, E. M., DeLeonibus, G. A., House, A., Kodger, J. V., Pearce, R. W., Shah, R., Levi, L., & Sandlers, Y. I. (2019) · Metabolites · doi:10.3390/metabo9120306 · Cited by 28
Comprehensive proteogenomic analysis of human embryonic and induced pluripotent stem cells
Parrotta, E. I., Scalise, S., Taverna, D., Angelis, M. T. D., Sarro, G., Gaspari, M., Santamaria, G., & Cuda, G. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14426 · Cited by 25 · cited 1×
“Additionally, a combined “multi-omics” study encompassing transcriptomic, proteomic, and phosphoproteomic profile analysis of reprogrammed iPSCs versus ESCs has demonstrated the presence of a small, but statistically significant, group of signaling pathways exclusively enriched in iPSCs, providing again evidence that…”
BackgroundSelf-citationGez, L. S., Hagalili, Y., Shainberg, A., & Atlas, D. (2012) · Biochemistry · doi:10.1021/bi301124a · Cited by 17
Sudden Death in an Infant With Angina, Restrictive Cardiomyopathy, and Coronary Artery Bridging
Greenway, S. C., Wilson, G. J., Wilson, J., George, K., & Kantor, P. F. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.969303 · Cited by 16
Badenes, S. M., Fernandes, T. G., Cordeiro, C. S. M., Boucher, S., Kuninger, D., Vemuri, M. C., Diogo, M. M., & Cabral, J. M. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155296 · Cited by 14
Automated Patch Clamp Recordings of Human Stem Cell-Derived Cardiomyocytes
Obergrussberger, A., Haarmann, C., Stölzle‐Feix, S., Becker, N., Ohtsuki, A., Brüggemann, A., George, M., & Fertig, N. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6661-5_4 · Cited by 12 · cited 1×
“Action potential is recorded using automated planar patch clamp platforms [87] or microelectrode arrays [88]; Ca2+ concentration is quantified using Ca2+-sensitive fluorophores [89]; cardiomyocyte contractility can be measured using muscular thin film [90] or dynamic monolayer force microscopy [91].”
Method
Cited by
Abdollahiyan, P., Oroojalian, F., & Mokhtarzadeh, A. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.036 · Cited by 99
Wen, Z.-J., Wang, Z., & Zhang, Y. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.157443 · Cited by 102
Replacing Animal Testing with Stem Cell-Organoids : Advantages and Limitations
Park, G., Rim, Y. A., Sohn, Y., Nam, Y., & Ju, J. H. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10723-5 · Cited by 92
“…that leads to scar formation and ultimately heart function failure, there are existing studies that explore iPSCs for novel therapeutic cures [ 84]. iPSC-derived progenitors such as human HCN4 + and human ESC derived ROR2 + , CD13 + , KDR + , PDGFRα + cells later generate cardiomyocytes [ 47].”
BackgroundUtility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Phang, R. J., Ritchie, R. H., Hausenloy, D. J., Lees, J. G., & Lim, S. Y. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac049 · Cited by 72
“stem cells with specific disease phenotypes, and they are usually not genetically matched with patients for transplantation.(307) The breakthrough”
BackgroundInfluential
Metadata
- Authors
- Parrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G.
- Affiliations
- Magna Graecia University (IT)
- Corresponding author
- Parrotta, Elvira Immacolata
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-19
- Volume
- 21
- Issue
- 12
- Pages
- 4354
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352327
- OpenAlex
- W3036591244
- Cited by
- 88
- References
- 212
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 15 · 2022: 12 · 2021: 17 · 2020: 2
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- induced pluripotent stem cells, iPSC-derived cardiomyocytes, cardiovascular disease modeling, cardiomyocyte death, myocardial fibrosis, heart failure, ventricular remodeling, cardiomyocyte hypertrophy, cardiomyocyte hyperplasia, cardiac inflammation, disease pathophysiology, stem cell therapy
- MeSH terms
- Cell Differentiation, Heart Diseases, Humans, Models, Biological, Signal Transduction, Disease Progression, Myocytes, Cardiac, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.